Since HER2-low breast cancer is amenable to targeted treatment with anti-HER2 antibody-drug conjugates, accurate assessment of patients’ HER2-low status is crucial for qualifying them for this treatment. This evidence concerns the gene ERBB2 and breast carcinoma.